On 1st June , 2021, Hunan Ouya Pharmaceutical Co., Ltd. held an awards and commendation meeting for company

first approved API. All departments reviewed the project history and looked forward to the future development

based on the theme of "New Journey, Start Again". 23th March, 2021, is an important day for Hunan Ouya-the

company's first API olmesartan medoxomil was transferred to the Active status in the platform of the Drug Evaluation

Center of the National Medical Products Administration which means that, the product is officially available for sale. 

The registration number is Y20200000249.

The Olmesartan medoxomil is the company’s first API. Starting from  plant renovation in October 2018, it took more

than 2 years to complete the project evaluation, plant renovation, R&D, and registration verification in April 2021.

We successfully passed the on-site inspection of GMP compliance by Hunan NMPA from 7th to 9th. On April 29th,

it received the "Notice on Drug GMP Inspection Results (No. HN-20210018)" issued by the Hunan NMPA. It is a new

chapter in the company's development history.

The commendation conference focuses on the theme of "New Journey, Start Again", reviewing the project

history and looking forward to future development

The company issues "Major Contribution Award", "Founding Award", "Dedication Award", "Inspection Award"

and "Production Efficiency Award" to the teams and individuals who have contributed to the project.